Dataset Information

SraX: A Novel Comprehensive Resistome Analysis Tool.

ABSTRACT: The accurate identification of the assortment of antibiotic resistance genes within a collection of genomes enables the discernment of intricate antimicrobial resistance (AMR) patterns while depicting the diversity of resistome profiles of the analyzed samples. The availability of large amount of sequence data, owing to the advancement of novel sequencing technologies, have conceded exciting possibilities for developing suitable AMR exploration tools. However, the level of complexity of bioinformatic analyses has raised as well, since the achievement of desired results involves executing several challenging steps. Here, sraX is proposed as a fully automated analytical pipeline for performing a precise resistome analysis. Our nominated tool is capable of scrutinizing hundreds of bacterial genomes in-parallel for detecting and annotating putative resistant determinants. Particularly, sraX presents unique features: genomic context analysis, validation of known mutations conferring resistance, illustration of drug classes and type of mutated loci proportions and integration of results into a single hyperlinked navigable HTML-formatted file. Furthermore, sraX also exhibits relevant operational features since the complete analysis is accomplished by executing a single-command step. The capacity and efficacy of sraX was demonstrated by re-analyzing 197 strains belonging to Enterococcus spp., from which we confirmed 99.15% of all detection events that were reported in the original study. sraX can be downloaded from https://github.com/lgpdevtools/srax.

SUBMITTER: Panunzi LG

PROVIDER: S-EPMC7025521 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

sraX: A Novel Comprehensive Resistome Analysis Tool.

Panunzi Leonardo G LG

Frontiers in microbiology 20200205

The accurate identification of the assortment of antibiotic resistance genes within a collection of genomes enables the discernment of intricate antimicrobial resistance (AMR) patterns while depicting the diversity of resistome profiles of the analyzed samples. The availability of large amount of sequence data, owing to the advancement of novel sequencing technologies, have conceded exciting possibilities for developing suitable AMR exploration tools. However, the level of complexity of bioinfor ...[more]

PMID: 32117104

Similar Datasets

Project description:BackgroundWith the advent of array-based techniques to measure methylation levels in primary tumor samples, systematic investigations of methylomes have widely been performed on a large number of tumor entities. Most of these approaches are not based on measuring individual cell methylation but rather the bulk tumor sample DNA, which contains a mixture of tumor cells, infiltrating immune cells and other stromal components. This raises questions about the purity of a certain tumor sample, given the varying degrees of stromal infiltration in different entities. Previous methods to infer tumor purity require or are based on the use of matching control samples which are rarely available. Here we present a novel, reference free method to quantify tumor purity, based on two Random Forest classifiers, which were trained on ABSOLUTE as well as ESTIMATE purity values from TCGA tumor samples. We subsequently apply this method to a previously published, large dataset of brain tumors, proving that these models perform well in datasets that have not been characterized with respect to tumor purity .ResultsUsing two gold standard methods to infer purity - the ABSOLUTE score based on whole genome sequencing data and the ESTIMATE score based on gene expression data- we have optimized Random Forest classifiers to predict tumor purity in entities that were contained in the TCGA project. We validated these classifiers using an independent test data set and cross-compared it to other methods which have been applied to the TCGA datasets (such as ESTIMATE and LUMP). Using Illumina methylation array data of brain tumor entities (as published in Capper et al. (Nature 555:469-474,2018)) we applied this model to estimate tumor purity and find that subgroups of brain tumors display substantial differences in tumor purity.ConclusionsRandom forest- based tumor purity prediction is a well suited tool to extrapolate gold standard measures of purity to novel methylation array datasets. In contrast to other available methylation based tumor purity estimation methods, our classifiers do not need a priori knowledge about the tumor entity or matching control tissue to predict tumor purity.

Dataset Information

SraX: A Novel Comprehensive Resistome Analysis Tool.

Publications

sraX: A Novel Comprehensive Resistome Analysis Tool.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets